natgillin/translations-raw huggingface dataset:
A process according to any one of the preceding claims, characterised in that said portion of the coarser slag material fraction is finely milled so that at least 60% by weight, preferably at least 80% by weight of the filler is formed by particles not bigger than 125 µm. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što se dio frakcije grublje troske fino melje tako da najmanje 60% težine, poželjno najmanje 80% težine punila bude formirano od čestica ne većih od 125 Pm.
A filler (32) according to claim 14 or 15, characterised in that it contains β-dicalcium silicate and per part of by weight of β-dicalcium silicate less than 0.8 parts by weight, preferably less than 0.65 parts by weight and more preferably less than 0.5 parts by weight of γ-dicalcium silicate. 
Punilo (32) prema zahtjevu 14 ili 15, naznačeno time što sadrži β-dikalcijev silikata i po dijelu težine β-dikalcijevog silikata manje od 0.8 težinskih dijelova, poželjno manje od 0.65 težinskih dijelova i poželjnije manje od 0.5 težinskih dijelova γ-dikalcijevog silikata.
A filler (32) for use in construction materials which contain bitumen or a hydraulic binding agent, such as asphalt, mortar and concrete, in particular a filler obtained by the process according to any one of the claims 1 to 13, which filler comprises slag material, characterised in that the filler (32) comprises crystalline phases which contain at least 1% by weight of β-dicalcium silicate and, per part by weight of β-dicalcium silicate, less than 0.8 parts by weight, preferably less than 0.65 parts by weight and more preferably less than 0.5 parts by weight of γ-dicalcium silicate, the content of γ-dicalcium silicate being less than 4% by weight, preferably less than 3% by weight and more preferably less than 2% by weight of said crystalline phases. 
Punilo (32) za uporabu u građevnim materijalima koji sadrže bitumen ili hidraulične vezne tvari, kao što je asfalt, žbuka i beton, posebno punilo koje se dobiva postupkom prema bilo kojem od zahtjeva 1 do 13, to punilo sadrži trosku, naznačeno time što punilo (32) sadrži kristalne faze koje sadrže najmanje 1%tež β-dikalcijevog silikata i, po dijelu težine β-dikalcijevog silikata, manje od 0.8 težinskih dijelova, poželjno manje od 0.65 težinskih dijelova i poželjnije manje od 0.5 težinskih dijelova γ-dikalcijevog silikata, sadržaj γ-dikalcijevog silikata je manji od 4%tež, poželjno manji od 3%tež i poželjnije manji od 2%tež kristalnih faza.
A filler according to any one of the claims 14 to 17, characterised in that the slag material of the filler comprises a stainless steel slag, in particular a stainless steel slag produced during the production of austenitic nickel-chromium steel and containing at least 50 mg/kg nickel and at least 1000 mg/kg chromium. 
Punilo prema bilo kojem od zahtjeva 14 do 17, naznačeno time što troska u punilu sadrži trosku nehrđajućeg čelika, posebno trosku nehrđajućeg čelika dobivenu tijekom proizvodnje austenitnog nikal-krom čelika i sadrži najmanje 50 mg/kg nikla i najmanje 1000 mg/kg kroma.
A concrete or mortar composition comprising a hydraulic binding agent, characterised in that it comprises a filler (32) according to any one of the claims 14 to 21, preferably in a amount of at least 2% by weight, more preferably of at least 3% by weight and most preferably of at least 5% by weight dry matter on the total dry matter of the composition. 
Smjesa betona ili žbuke koja sadrži hidrauličnu veznu tvar, naznačena time što sadrži punilo (32) prema bilo kojem od zahtjeva 14 do 21, poželjno u količini od najmanje 2%tež, poželjnije najmanje 3%tež i najpoželjnije barem 5%tež suhe tvari prema ukupnoj suhoj tvari smjese.
A composition according to claim 23, characterised in that it is a high-fluidity concrete composition, in particular a self-compacting concrete composition which comprises a superplasticizer, for example a polycarboxylate. 
Smjesa prema zahtjevu 23, naznačena time što je to visoko-fluidna betonska smjesa, posebno samo-kompaktna betonska smjesa koja sadrži superplastifikator, na primjer polikarboksilat.
An asphalt composition according to claim 25, characterised in that at least 20% by weight, preferably at least 40% by weight and more preferably at least 60% by weight of the filler fraction consists of said filler. 
Smjesa asfalta prema zahtjevu 25, naznačena time što se najmanje 20%tež, poželjno najmanje 40%tež i poželjnije najmanje 60%tež frakcije punila sastoji od navedenog punila.
Use of an antibiotic for the preparation of a pharmaceutical composition for the prevention of Lyme disease, or for the elimination of Borrelia burgdorferi resulting from a tick bite, wherein the pharmaceutical composition is to be adminstered topically. 
Uporaba antibiotika, naznačena time, da se koristi u proizvodnji farmaceutskog sastava za prevenciju lajmske bolesti, ili za eliminaciju Borrelia burgdorferi koja je rezultat uboda krpelji, pri čemu se farmaceutski sastav treba primjenjivati topikalno.
A pharmaceutical composition for use in the prevention of Lyme disease or for the elimination of Borrelia burgdorferi (including spirochetal, cystic and/or spherical forms) resulting from a tick bite, comprising an antibiotic, a volatile solvent (defined as water or a solvent more volatile than water) and, optionally, a solidifying agent, wherein the pharmaceutical composition is to be administered topically. 
Farmaceutski sastav, naznačen time, da se koristi za prevenciju lajmske bolesti, ili za eliminaciju Borrelia burgdorferi (uključujući spiroketalne, cističke i/ili sferične oblike) koja je rezultat uboda krpelji, te da obuhvaća antibiotik, isparivo otapalo (definirano kao voda ili otapalo više isparivo nego voda) i opcijski sredstvo zgušnjavanja, pri čemu se farmaceutski sastav treba primjenjivati topikalno.
A topical pharmaceutical composition for use according to claim 2 comprising in addition a non-volatile solvent (defined as a solvent less volatile than water). 
Topikalni farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da dodatno obuhvaća neisparivo otapalo (definirano kao otapalo manje isparivo nego voda).
A topical pharmaceutical composition for use according to claim 2 or 3, wherein the antibiotic is present from about 1 wt% to about 30 wt%, based on the total weight of the composition. 
Topikalni farmaceutski sastav za uporabu prema zahtjevu 2 ili 3, naznačen time, da je antibiotik prisutan od oko 1 masenih % do oko 30 masenih %, bazirano na ukupnoj masi sastava.
A topical pharmaceutical composition for use according to any one of claims 2 to 5, wherein the solidifying agent is present from 5 wt% to 60 wt%, based on the total weight of the composition. 
Topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 2 do 5, naznačen time, da je sredstvo zgušnjavanja prisutno od 5 masenih % do 60 masenih %, bazirano na ukupnoj masi sastava.
A use or a topical pharmaceutical composition for use according to any one of claims 1 to 7, wherein the antibiotic is selected from the group comprising azithromycin, clarithromycin, dirithromycin, roxithromycin, telithromycin, troleandomycin, chlortetracycline, demeclocycline, minocycline, oxytetracycline and methacycline. 
Uporaba ili topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 1 do 7, naznačena time, da je antibiotik odabran iz skupine koja sadrži azitromicin, klaritromicin, diritromicin, roksitromicin, telitromicin, troleandomicin, klortetraciklin, demeklociklin, minociklin, oksitetraciklin i metaciklin.
A use or a topical pharmaceutical composition for use according to any one of claims 1 to 7, wherein the antibiotic is azithromycin. 
Uporaba ili topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 1 do 7, naznačena time, da antibiotik je azitromicin.
is hydrogen or C1-6alkyl; or R12 and R13 taken together with the nitrogen atom to which they are substituted form imidazolyl. 
je vodik ili C1-6alkil; ili R12 i R13 uzeti zajedno sa atomom dušika na koji su supstituirani formiraju imidazolil.
is a single bond or a double bond, (b) is a single bond or a double bond, provided that at least one of (a) and (b) is a single bond; 
je jednostruka ili dvostruka veza, (b) je jednostruka ili dvostruka veza, uz uvjet da barem jedan od (a) i (b) bude jednostruka veza;
or a pharmaceutically acceptable salt thereof. 
ili farmaceutski prihvatljiva sol tog spoja.
A composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
Smjesa, naznačena time što sadrži spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
or -NR3R4 forms RF, which is optionally substituted with one or more R10 groups; 
ili -NR3R4 tvori RF, koji je izborno supstituiran s jednom ili više skupina R10;
A compound according to claim 1, wherein R1 is RA, which is optionally substituted with one or more R7 groups; and RA is a C3-C10 cycloalkyl group, which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic, which may be fused to either 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je RA, koji je izborno supstituiran s jednom ili više skupina R7; i RA je C3-C10 cikloalkilna skupina, koja može biti bilo monociklička ili, kada je u prstenu dovoljan broj atoma, policiklička, te koja može biti kondenzirana bilo s
A compound according to claim 3 wherein RA is a monocyclic C5-C7 cycloalkyl group. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što RA je monociklička C5-C7 cikloalkilna skupina.
A compound according to claim 1 wherein R1 is RB, which is optionally substituted with one or more R7 groups. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je RB, koji je izborno supstituiran s jednom ili više skupina R7.
A compound according to claim 1 wherein R1 is RC, which is optionally substituted with one or more R7 groups. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je RC, koji je izborno supstituiran s jednom ili više skupina R7.
A compound according to claim 1 wherein R1 is RD, which is optionally substituted with one or more R7 groups. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je RD, koji je izborno supstituiran s jednom ili više skupina R7.
A compound according to claim 22 wherein R3 is hydrogen, C1-C4 alkyl, which is optionally substituted with one or more R8 groups, or RE, which is optionally substituted with one or more R9 groups; and wherein RE is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur. 
Spoj u skladu s patentnim zahtjevom 22, naznačen time što R3 je vodik, C1-C4 alkil, koji je izborno supstituiran s jednom ili više skupina R8, ili RE, koji je izborno supstituiran s jednom ili više skupina R9; te gdje RE je monociklički zasićeni prstenasti sustav, koji sadrži između 3 i 7 atoma u prstenu, od kojih je najmanje jedan heteroatom, kojeg se bira između dušika, kisika i sumpora.
A compound according to claim 23 wherein R3 is C1-C4 alkyl, which is optionally substituted with one or more R8 groups and wherein R8 is halo, phenyl, C1-C6 alkoxyphenyl, OR12, NR12R13, NR12CO2R14, CO2R12, CONR12R13, RG or RH, the last two of which are optionally substituted with one or more R9 groups. 
Spoj u skladu s patentnim zahtjevom 23, naznačen time što R3 je C1-C4 alkil, koji je izborno supstituiran s jednom ili više skupina R8, te gdje R8 je halogen, fenil, C1-C6 alkoksifenil, OR12, NR12R13, NR12CO2R14, CO2R12, CONR12R13, RG ili RH, od kojih su potonja dva izborno supstituirana s jednom ili više skupina R9.
A compound according to claim 26 wherein R8 is hydroxy, methoxy, methoxyphenyl, NH2, NHMe, NMe2, NHCO2tBu, NMeCO2tBu, CO2H, CONHMe, RG or RH, the last two of which are optionally substituted with one or more R9 groups. 
Spoj u skladu s patentnim zahtjevom 26, naznačen time što R8 je hidroksi, metoksi, metoksifenil, NH2, NHMe, NMe2, NHCO2tBu, NMeCO2tBu, CO2H, CONHMe, RG ili RH, od kojih su potonja dva izborno supstituirana s jednom ili više skupina R9.
A compound according to claim 27 wherein R8 is RH, which is optionally substituted with one or more R9 groups and wherein RH is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms. 
Spoj u skladu s patentnim zahtjevom 27, naznačen time što R8 je RH, koji je izborno supstituiran s jednom ili više skupina R9, te gdje RH je 5- ili 6-eročlani heteroaromatski prsten, koji sadrži do dva atoma dušika.
A compound according to claim 50 wherein R6 is C1-C4 alkyl or C1-C4 haloalkyl, each of which is optionally substituted by C1-C4 alkoxy, cyclopropyl, cyclobutyl, tetrahydrofuranyl, tetrahydropyranyl or pyridinyl, or R6 is hydrogen or tetrahydropyranyl. 
Spoj u skladu s patentnim zahtjevom 50, naznačen time što R6 je C1-C4 alkil ili C1-C4 halogenalkil, od kojih je svaki izborno supstituiran s C1-C4 alkoksi, ciklopropil, ciklobutil, tetrahidrofuranil, tetrahidropiranil ili piridinil, ili R6 je vodik ili tetrahidropiranil.
is hydrogen, C1-C4 alkyl, which is optionally substituted with one or more R8 groups, or RE which is optionally substituted with one or more R9 groups; 
je vodik, C1-C4 alkil, koji je izborno supstituiran s jednom ili više skupina R8, ili RE, koji je izborno supstituiran s jednom ili više skupina R9;
A compound according to any one of claims 1 to 61, for use in accordance with claim 57 as a medicament for the treatment of a disease or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 61, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 57 kao medikament za liječenje bolesti ili stanja za koje se zna, ili se može pokazati, da inhibiranje PDE5 daje povoljan učinak.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 61 and a second pharmaceutically active agent selected from the group consisting of aspirin, angiotensin II receptor antagonists, calcium channel blockers, beta-blockers, CI1027, CCR5 receptor antagonists, imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics, alpha adrenergic antagonists, ACE (angiotensin converting enzyme) inhibitors, aldosterone receptor antagonists, neutral endopeptidase inhibitors, antidiabetic agents, sulfonylureas, glitazones, cholesterol lowering agents, and alpha-2-delta ligands. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 61 i dodatno farmaceutski aktivno sredstvo, koje se bira iz skupine koju čine aspirin, antagonisti receptora angiotenzina II, blokatori kalcijskih kalnala, β-blokatori, CI1027, antagonisti receptora CCR5, imidazolini, antihipertenzivna sredstva tipa sGCa (topivi aktivatori gvanilat-ciklaze), diuretici, a-adrenergički antagonisti, inhibitori ACE (angiotenzin-konvertirajući enzim), antagonisti aldosteronskog receptora, inhibitori neutralne endopeptidaze, antidijabetička sredstva, sulfoniluree, glitazoni, sredstva za snižavanje razine kolesterola i a-2-δ ligandi.
A compound of formula (III) wherein R1, R2, R6 and Y are as defined in claim 1 and RA is C1-C6 alkyl or benzyl, with the proviso that the compound is not a compound of formula: wherein R1, R2 and R6 are as defined in claim 1. 
Spoj formule (III) [image] naznačen time što R1, R2, R6 i Y su definirani kao u patentnom zahtjevu 1, a RA je C1-C6 alkil ili benzil, uz uvjet da spoj nije spoj formule: [image] gdje R1, R2 i R6 su definirani kao u patentnom zahtjevu 1.
A compound of formula (V) wherein R6 and Y are as defined in claim 1 and RA is C1-C6 alkyl or benzyl, with the proviso that the compound of formula (V) is not a compound of formula: wherein R6 is as defined in claim 1. 
Spoj formule (V) [image] naznačen time što R6 i Y su definirani kao u patentnom zahtjevu 1, a RA je C1-C6 alkil ili benzil, uz uvjet da spoj formule (V) nije spoj formule:
The 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, the pharmaceutically acceptable salt thereof or the hydrate thereof as defined in any one of claims 1 to 4 for use in the treatment and prevention of schizophrenia, anxiety, depression, bipolar disorder, epilepsy, drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, dyskinesia associated with muscular rigidity, cerebral ischemia, cerebral failure, myelopathy and head trauma. 
Derivat 2-amino-biciklo[3.1.0]heksan-2,6-dikarboksilnog estera, njegova farmaceutski prihvatljiva sol ili hidrat kako se definira u bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da se koristi u liječenju i prevenciji shizofrenije, tjeskobe, depresije, bipolarnog poremećaja, epilepsije, ovisnosti o lijekovima, kognitivnih poremećaja, Alzheimerove bolesti, Huntingtonove koreje, Parkinsonove bolesti, diskinezije povezane s mišićnom rigidnosti, cerebralne ishemije, zatajenja moždanih funkcija, mijelopatije i trauma glave.
wherein in residues R2 to R8 alkyl or alkylene can optionally be substituted one or more times by halogen; 
gdje u ostacima R2 do R8 alkil ili alkilen mogu jednom ili više puta biti izborno supstituirani s halogenom;
or wherein (C6-C10)aryl is vicinally substituted by a O-(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to; 
ili gdje (C6-C10)aril je vicinalno supstituiran s O-(C1-C4)alkilen-O skupinom, gdje 5-8-eročlani prsten se tvori zajedno s atomima ugljika na koje su vezani atomi kisika;
or R2 is a (C1-C4)alkylene bound to the cycloalkyl amine, in which the (C1-C4) alkylene forms a second bond to a different carbon atom of the cycloalkyl amine ring and forms, together with carbon atoms of cycloalkyl amine, a second, 4-8 membered ring; 
ili R2 je (C1-C4)alkilen, vezan na cikloalkilamin, gdje (C1-C4)alkilen tvori drugu vezu na različiti atom ugljika u cikloalkilaminskom prstenu, te, zajedno s atomima ugljika u cikloalkilaminu, tvori drugi, 4-8-eročlani prsten;
or R6 and R6', together with the N-atom to which they are attached, form a (C5-C6)heterocyclyl group. 
ili R6 i R6', zajedno s N-atomom na kojeg su vezani, tvore (C5-C6)heterociklilnu skupinu.
A compound according to claim 1 selected from the group of 6-(4-Allyl-4-amino-cyclohexyloxy)-7-chloro-2H-isoquinolin-1-one, 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine -(4-Alil-4-aminocikloheksiloksi)-7-klor-2H-izokinolin-1-on,
represents hydrogen, lower alkyl, or hydroxymethyl; 
predstavlja vodik, niži alkil, ili hidroksimetil;
n represents the integer 0 or 1; 
n predstavlja cijeli broj 0 ili 1;
and configurational isomers, optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-form, as well as pharmaceutically acceptable salts, solvent complexes, and morphological forms, and inert carrier material; 
i konfiguracijske izomere, optički čiste enantiomere, mješavine enantiomera kao što su racemati, diastereomeri, mješavine diastereomera, diastereomerni racemati, mješavine diastereomernih racemata i mezo-oblik, kao i farmaceutski prihvatljive soli, komplekse otapala, i morfološke oblike, te inertne prijenosne materijale;
Pharmaceutical composition according to claim 1 in which said thiazolidin-4-one derivatives are the (Z,Z)-isomers according to General Formula (I) in claim 1. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da spomenuti derivati tiazolidin-4-ona su (Z,Z)-izomeri prema Općoj formuli (I) u zahtjevu 1.
represents hydrogen; hydroxy; lower alkoxy; lower alkyl or halogen; 
predstavlja vodik; hidroksi; niži alkoksi; niži alkil; ili halogen;
m represents the integer 1 or 2; 
m predstavlja cijeli broj 1 ili 2;
Thiazolidin-4-one derivatives according to any of claims 18 and 19 wherein R14 represents an unsubstituted, a mono- or disubstituted phenyl group, substituted with methyl or halogen, m represents the integer 0, R17, R18, R19, R20 and R23 represent hydrogen. 
Derivati tiazolidin-4-ona prema zahtjevima 4 i 5, naznačeni time, da R14 predstavlja nesupstituiranu, ili a mono- ili di-supstituiranu fenilnu skupinu, supstituiranu metilom ili halogenom, m predstavlja cijeli broj 0, a R17, R18, R19, R20 i R23 predstavljaju vodik.
A and B are independently selected from: 
A i B su neovisno odabrani od:
A-B together form a (C2-C6)bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R8 groups, and which bridge optionally contains -HC=CH- within the (C2-C6)bridge; wherein the piperazine ring that is fused to the Q group can be in the endo- or exo- conformation with respect to the A-B bridge; or 
A-B koji zajedno formiraju (C2-C6)most, koji je nesupstituiran ili supstituiran s 1, 2 ili 3 neovisno odabrane skupine R8, i gdje most opcionalno sadrži -HC=CH- unutar (C2-C6)mosta; gdje piperazinski prsten koji je spojen na fenilnu skupinu može biti u endo- ili egzo- konformaciji u odnosu na A-B most; ili
A-B together form a -CH2-N(Ra)-CH2- bridge, a wherein the piperazine ring that is fused to the Q group can be in the endo- or exo-conformation with respect to the A-B bridge; 
A-B zajedno formiraju -CH2-N(Ra)-CH2- most, [image] most, ili [image] most; gdje piperazinski prsten koji je spojen na fenilnu skupinu može biti u endo- ili egzo- konformaciji u odnosu na A-B most;
The compound according to any one of claims 1-12, wherein A-B together form a (C2-C6)bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R8 groups, and which bridge optionally contains -HC=CH- within the (C2-C6)bridge 
Spoj prema bilo kojem zahtjevu od 1 do 12, naznačen time da A-B zajedno formiraju (C2-C6)most, koji se nesupstituiran ili supstituiran s 1, 2 ili 3 neovisno odabrane skupine R8, i čiji most opcionalno sadrži -HC=CH unutar (C2-C6)mosta.
The compound according to claim 13, wherein A-B together form a (C2)bridge, a -HC=CH- bridge, or a (C3)bridge. 
Spoj prema zahtjevu 13, naznačen time da A-B zajedno formiraju (C2)most, -HC=CH- most, ili (C3)most.
A compound according to any one of claims 1-11 for use in the treatment of pain, a memory disorder, obesity, constipation, urinary incontinence, anxiety, cough, diarrhea, high blood pressure, epilepsy, anorexia/cachexia, or drug abuse in an animal. 
Spoj prema bilo kojem zahtjevu od 1 do 19, naznačen time da je za upotrebu u liječenju boli, poremećaja pamćenja, pretilosti, konstipacije, urinarne inkontinencije, anksioznosti, kašlja, dijareje, visokog krvnog tlaka, epilepsije, anoreksije/kaheksije, ili zloupotrebe droge kod životinja.
wherein the piperazine ring that is fused to the Q group can be in the endo- or exo- conformation with respect to the A-B bridge; 
gdje piperazinski prsten koji je spojen na fenilnu skupinu može biti u endo- ili egzo- konformaciji u odnosu na A-B most;
Pharmaceutical composition containing as active ingredient crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 or 14 and at least one suitable additive and/or auxiliary substance. 
Farmaceutski sastav koji kao aktivni sastojak sadrži kristalni oblik A (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida prema zahtjevima od 1 do 3, naznačen time da je za upotrebu u liječenju boli ili urinarne inkontinencije.
a crankshaft (108), rotating about a crankshaft axis (110) of the engine (100); 
koljenasto vratilo (108) koje se okreće oko osi koljenastog vratila (110);
stitching said folded gusset (14') directly onto said mattress panel (1') along a first seam (15) inwardly recessed from the edge of the mattress panel, in correspondence with said fold dividing the gusset into two parts. 
šivanje presavinutog ušitka (14’) izravno na oblogu madraca (1’) duž prvog šava (15) okrenutog prema unutra od ruba obloge madraca, što odgovara mjestu gdje mjesto presavijanja dijeli ušitak na dva dijela;
said first seam (15) passing through the full thickness of said mattress panel (1') so that it is visible on the outer side of the mattress panel. 
prvi šav (15) prolazi punom debljinom obloge madraca (1’) tako da je vidljiv na vanjskoj strani obloge madraca.